Pharmacokinetic study of niosome encapsulated insulin

G. Khaksa, R. D'Souza, S. Lewis, N. Udupa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Pharmacokinetic profile and hypoglycemic effect, after intraperitoneal injection of insulin and insulin encapsulated in niosomes were determined in diabetic rats. Niosomes (non-ionic surfactant vesicles) of different doses and different lipid compositions were prepared by lipid layer hydration method. Plasma samples were collected at specified time intervals and plasma concentration of insulin was determined by HPLC. Blood glucose level was estimated spectrophotometrically using commercial glucose assay kit. In vitro release and pharmacokinetic profile of niosomal formulation and free insulin were evaluated. Though there was a slight delay in the in vitro drug release due to cholesterol content in the niosomes, there was no difference between the two preparations when plasma levels were compared in vivo. Niosomes significantly reduced the blood glucose level in diabetic rats. Fall in blood glucose level was almost 92% of initial value. In case of the niosomal form the half-life of insulin was prolonged by 4 -5hr in contrast to 2hr for free drug. Niosomes maintained the plasma insulin level up to 12hr, but free drug was cleared quickly. The area under the plasma concentration-time curve for niosomal forms was, 26.07°± 0.99 mIU. hr/ml and for free insulin was 11.722 ± 1.10mIU. hr/ml. More than 80% of the drug was successfully encapsulated to give a formulation with sustained release characteristics. Entrapment efficiency increased with increasing lipid concentration and decreased with increasing drug concentration. The results showed that insulin entrapped in niosomes prolongs the existence of drug in the body therefore increasing its therapeutic value.

Original languageEnglish
Pages (from-to)901-905
Number of pages5
JournalIndian Journal of Experimental Biology
Volume38
Issue number9
Publication statusPublished - 2000

Fingerprint

Pharmacokinetics
Insulin
Liposomes
Glucose
Plasmas
Pharmaceutical Preparations
Lipids
Blood Glucose
Blood
Rats
Cholesterol
Nonionic surfactants
Intraperitoneal Injections
Hypoglycemic Agents
Surface-Active Agents
Hydration
Half-Life
Assays
High Pressure Liquid Chromatography
Chemical analysis

All Science Journal Classification (ASJC) codes

  • Bioengineering

Cite this

@article{e60b7e4fb9ef45e5989479a6119cf365,
title = "Pharmacokinetic study of niosome encapsulated insulin",
abstract = "Pharmacokinetic profile and hypoglycemic effect, after intraperitoneal injection of insulin and insulin encapsulated in niosomes were determined in diabetic rats. Niosomes (non-ionic surfactant vesicles) of different doses and different lipid compositions were prepared by lipid layer hydration method. Plasma samples were collected at specified time intervals and plasma concentration of insulin was determined by HPLC. Blood glucose level was estimated spectrophotometrically using commercial glucose assay kit. In vitro release and pharmacokinetic profile of niosomal formulation and free insulin were evaluated. Though there was a slight delay in the in vitro drug release due to cholesterol content in the niosomes, there was no difference between the two preparations when plasma levels were compared in vivo. Niosomes significantly reduced the blood glucose level in diabetic rats. Fall in blood glucose level was almost 92{\%} of initial value. In case of the niosomal form the half-life of insulin was prolonged by 4 -5hr in contrast to 2hr for free drug. Niosomes maintained the plasma insulin level up to 12hr, but free drug was cleared quickly. The area under the plasma concentration-time curve for niosomal forms was, 26.07°± 0.99 mIU. hr/ml and for free insulin was 11.722 ± 1.10mIU. hr/ml. More than 80{\%} of the drug was successfully encapsulated to give a formulation with sustained release characteristics. Entrapment efficiency increased with increasing lipid concentration and decreased with increasing drug concentration. The results showed that insulin entrapped in niosomes prolongs the existence of drug in the body therefore increasing its therapeutic value.",
author = "G. Khaksa and R. D'Souza and S. Lewis and N. Udupa",
year = "2000",
language = "English",
volume = "38",
pages = "901--905",
journal = "Journal of scientific & industrial research. C. Biological sciences",
issn = "0019-5189",
publisher = "National Institute of Science Communication",
number = "9",

}

Pharmacokinetic study of niosome encapsulated insulin. / Khaksa, G.; D'Souza, R.; Lewis, S.; Udupa, N.

In: Indian Journal of Experimental Biology, Vol. 38, No. 9, 2000, p. 901-905.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetic study of niosome encapsulated insulin

AU - Khaksa, G.

AU - D'Souza, R.

AU - Lewis, S.

AU - Udupa, N.

PY - 2000

Y1 - 2000

N2 - Pharmacokinetic profile and hypoglycemic effect, after intraperitoneal injection of insulin and insulin encapsulated in niosomes were determined in diabetic rats. Niosomes (non-ionic surfactant vesicles) of different doses and different lipid compositions were prepared by lipid layer hydration method. Plasma samples were collected at specified time intervals and plasma concentration of insulin was determined by HPLC. Blood glucose level was estimated spectrophotometrically using commercial glucose assay kit. In vitro release and pharmacokinetic profile of niosomal formulation and free insulin were evaluated. Though there was a slight delay in the in vitro drug release due to cholesterol content in the niosomes, there was no difference between the two preparations when plasma levels were compared in vivo. Niosomes significantly reduced the blood glucose level in diabetic rats. Fall in blood glucose level was almost 92% of initial value. In case of the niosomal form the half-life of insulin was prolonged by 4 -5hr in contrast to 2hr for free drug. Niosomes maintained the plasma insulin level up to 12hr, but free drug was cleared quickly. The area under the plasma concentration-time curve for niosomal forms was, 26.07°± 0.99 mIU. hr/ml and for free insulin was 11.722 ± 1.10mIU. hr/ml. More than 80% of the drug was successfully encapsulated to give a formulation with sustained release characteristics. Entrapment efficiency increased with increasing lipid concentration and decreased with increasing drug concentration. The results showed that insulin entrapped in niosomes prolongs the existence of drug in the body therefore increasing its therapeutic value.

AB - Pharmacokinetic profile and hypoglycemic effect, after intraperitoneal injection of insulin and insulin encapsulated in niosomes were determined in diabetic rats. Niosomes (non-ionic surfactant vesicles) of different doses and different lipid compositions were prepared by lipid layer hydration method. Plasma samples were collected at specified time intervals and plasma concentration of insulin was determined by HPLC. Blood glucose level was estimated spectrophotometrically using commercial glucose assay kit. In vitro release and pharmacokinetic profile of niosomal formulation and free insulin were evaluated. Though there was a slight delay in the in vitro drug release due to cholesterol content in the niosomes, there was no difference between the two preparations when plasma levels were compared in vivo. Niosomes significantly reduced the blood glucose level in diabetic rats. Fall in blood glucose level was almost 92% of initial value. In case of the niosomal form the half-life of insulin was prolonged by 4 -5hr in contrast to 2hr for free drug. Niosomes maintained the plasma insulin level up to 12hr, but free drug was cleared quickly. The area under the plasma concentration-time curve for niosomal forms was, 26.07°± 0.99 mIU. hr/ml and for free insulin was 11.722 ± 1.10mIU. hr/ml. More than 80% of the drug was successfully encapsulated to give a formulation with sustained release characteristics. Entrapment efficiency increased with increasing lipid concentration and decreased with increasing drug concentration. The results showed that insulin entrapped in niosomes prolongs the existence of drug in the body therefore increasing its therapeutic value.

UR - http://www.scopus.com/inward/record.url?scp=0033791440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033791440&partnerID=8YFLogxK

M3 - Article

C2 - 12561948

AN - SCOPUS:0033791440

VL - 38

SP - 901

EP - 905

JO - Journal of scientific & industrial research. C. Biological sciences

JF - Journal of scientific & industrial research. C. Biological sciences

SN - 0019-5189

IS - 9

ER -